210 related articles for article (PubMed ID: 37444563)
1. Identification of a Novel SSTR3 Full Agonist for the Treatment of Nonfunctioning Pituitary Adenomas.
Modena D; Moras ML; Sandrone G; Stevenazzi A; Vergani B; Dasgupta P; Kliever A; Gulde S; Marangelo A; Schillmaier M; Luque RM; Bäuerle S; Pellegata NS; Schulz S; Steinkühler C
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444563
[TBL] [Abstract][Full Text] [Related]
2. The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells.
Di Muro G; Catalano R; Treppiedi D; Barbieri AM; Mangili F; Marra G; Di Bari S; Esposito E; Nozza E; Lania AG; Ferrante E; Locatelli M; Modena D; Steinkuhler C; Peverelli E; Mantovani G
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612419
[TBL] [Abstract][Full Text] [Related]
3. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary.
Lee M; Lupp A; Mendoza N; Martin N; Beschorner R; Honegger J; Schlegel J; Shively T; Pulz E; Schulz S; Roncaroli F; Pellegata NS
Endocr Relat Cancer; 2015 Feb; 22(1):111-9. PubMed ID: 25515731
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
[TBL] [Abstract][Full Text] [Related]
5. Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors.
Streuli J; Harris AG; Cottiny C; Allagnat F; Daly AF; Grouzmann E; Abid K
Neuropeptides; 2018 Apr; 68():84-89. PubMed ID: 29523357
[TBL] [Abstract][Full Text] [Related]
6. Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma).
Yu B; Zhang Z; Song H; Chi Y; Shi C; Xu M
Med Sci Monit; 2017 Apr; 23():1947-1955. PubMed ID: 28434012
[TBL] [Abstract][Full Text] [Related]
7. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.
Shimon I
Endocrine; 2003 Apr; 20(3):265-9. PubMed ID: 12721506
[TBL] [Abstract][Full Text] [Related]
9. Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors.
Gulde S; Wiedemann T; Schillmaier M; Valença I; Lupp A; Steiger K; Yen HY; Bäuerle S; Notni J; Luque R; Schmid H; Schulz S; Ankerst DP; Schilling F; Pellegata NS
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205778
[TBL] [Abstract][Full Text] [Related]
10. Estrogen Receptor α, a Sex-Dependent Predictor of Aggressiveness in Nonfunctioning Pituitary Adenomas: SSTR and Sex Hormone Receptor Distribution in NFPA.
Øystese KA; Casar-Borota O; Normann KR; Zucknick M; Berg JP; Bollerslev J
J Clin Endocrinol Metab; 2017 Sep; 102(9):3581-3590. PubMed ID: 28911153
[TBL] [Abstract][Full Text] [Related]
11. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo.
Nielsen S; Mellemkjaer S; Rasmussen LM; Ledet T; Olsen N; Bojsen-Møller M; Astrup J; Weeke J; Jørgensen JO
J Endocrinol Invest; 2001 Jun; 24(6):430-7. PubMed ID: 11434667
[TBL] [Abstract][Full Text] [Related]
12. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.
Iacovazzo D; Carlsen E; Lugli F; Chiloiro S; Piacentini S; Bianchi A; Giampietro A; Mormando M; Clear AJ; Doglietto F; Anile C; Maira G; Lauriola L; Rindi G; Roncaroli F; Pontecorvi A; Korbonits M; De Marinis L
Eur J Endocrinol; 2016 Feb; 174(2):241-50. PubMed ID: 26586796
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.
Florio T; Barbieri F; Spaziante R; Zona G; Hofland LJ; van Koetsveld PM; Feelders RA; Stalla GK; Theodoropoulou M; Culler MD; Dong J; Taylor JE; Moreau JP; Saveanu A; Gunz G; Dufour H; Jaquet P
Endocr Relat Cancer; 2008 Jun; 15(2):583-96. PubMed ID: 18509006
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
15. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
[TBL] [Abstract][Full Text] [Related]
16. High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma.
Behling F; Honegger J; Skardelly M; Gepfner-Tuma I; Tabatabai G; Tatagiba M; Schittenhelm J
Int J Endocrinol; 2018; 2018():1763735. PubMed ID: 30627156
[TBL] [Abstract][Full Text] [Related]
17. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
18. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
Schmid HA; Silva AP
J Endocrinol Invest; 2005; 28(11 Suppl International):28-35. PubMed ID: 16625842
[TBL] [Abstract][Full Text] [Related]
19. Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.
Ramírez C; Cheng S; Vargas G; Asa SL; Ezzat S; González B; Cabrera L; Guinto G; Mercado M
J Clin Endocrinol Metab; 2012 May; 97(5):1745-51. PubMed ID: 22419713
[TBL] [Abstract][Full Text] [Related]
20. Selective Interactions of Mouse Melanocortin Receptor Accessory Proteins with Somatostatin Receptors.
Wang M; Xu J; Lei XW; Zhang C; Liu SY; Jin LN; Zhang C
Cells; 2022 Jan; 11(2):. PubMed ID: 35053382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]